Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Mirae Asset Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Mirae Asset Capital

Mirae Asset Capital

Operating

Seoul-based South Korean firm specializing in customized investment financing solutions.

Location
Seoul, Seoul, KR
Founded
1997
Firm
Compare
Portfolio
Employees
News
Website

Investments

Accent Therapeutics
Accent Therapeutics

Total Raised

$178M

Rounds

3

Series C$75MJanuary 2024
Neocis
Neocis

Total Raised

$183.1M

Rounds

9

Series D$20MJanuary 2024
Rome Therapeutics
Rome Therapeutics

Total Raised

$199M

Rounds

3

Series B$72MSeptember 2023
Crossbow Therapeutics
Crossbow Therapeutics
Series B

Total Raised

$157M

Rounds

2

Series A$80MJuly 2023
Kream
Kream

Total Raised

$410.6B

Rounds

4

Series C$220.6BMarch 2023
Series B$100BOctober 2021
Weka
Weka

Total Raised

$293.9M

Rounds

7

Series D$135MNovember 2022
Ascend Elements
Ascend Elements

Total Raised

$1.5B

Rounds

13

Series C$200MOctober 2022
AmazeVR
AmazeVR

Total Raised

$50.8M

Rounds

6

Series B$20MSeptember 2022
Series B$5.5MJanuary 2022
Series B$9.5MApril 2021
WiTricity
WiTricity

Total Raised

$176M

Rounds

10

Series Unknown$63MAugust 2022
Cleerly
Cleerly

Total Raised

$280.5M

Rounds

3

Series C$223MJuly 2022
Aspen Neuroscience
Aspen Neuroscience

Total Raised

$264M

Rounds

4

Series B$147.5MMay 2022
Syntiant
Syntiant

Total Raised

$91.4M

Rounds

6

Series D$56.4MMarch 2022
ThorDrive
ThorDrive

Total Raised

$26.1M

Rounds

3

Series A$16.7MFebruary 2022
Dewpoint Therapeutics
Dewpoint Therapeutics

Total Raised

$287M

Rounds

3

Series C$150MFebruary 2022
QueryPie
QueryPie
Seed

Total Raised

$21B

Rounds

4

Seed$21BDecember 2021
Apeel
Apeel

Total Raised

$719.1M

Rounds

12

Series E$250MAugust 2021
Woebot Health
Woebot Health

Total Raised

$123.3M

Rounds

4

Series B$90MJuly 2021
Insilico Medicine
Insilico Medicine

Total Raised

$401.3M

Rounds

11

Series C$255MJune 2021
Valo Health
Valo Health

Total Raised

$460M

Rounds

5

Series B$190MJanuary 2021
Senti Biosciences
Senti Biosciences
Public

Total Raised

$215.9M

Rounds

11

Series B$105MJanuary 2021